Recurrent urinary tract infection genetic risk: a systematic review and gene network analysis.

Gene expression Genes Recurrent urinary tract infection Urinary tract infection

Journal

International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041

Informations de publication

Date de publication:
02 Nov 2023
Historique:
received: 05 07 2023
accepted: 11 10 2023
medline: 2 11 2023
pubmed: 2 11 2023
entrez: 2 11 2023
Statut: aheadofprint

Résumé

The development of recurrent urinary tract infections (rUTIs) is not completely understood. This review is aimed at investigating the connection between genetics and rUTIs and summarizing the results of studies that have documented variations in gene expression among individuals with rUTIs compared with healthy individuals. A systematic search was conducted in Cochrane, Ovid, and PubMed, limiting the results to articles published between 1 January 2000, and 5 July 2022. Only studies comparing the difference in gene expression between individuals with rUTI and healthy individuals utilizing molecular techniques to measure gene expression in blood or urine samples were included in this systematic review. Gene network and pathways analyses were performed using Cytoscape software, with input data obtained from our systematic review of differentially expressed genes in rUTIs. Six studies met our criteria for inclusion. The selected studies used molecular biology methods to quantify gene expression data from blood specimens. The analysis revealed that gene expressions of CXCR1 and TLR4 decreased, whereas CXCR2, TRIF, and SIGIRR increased in patients with rUTI compared with healthy controls. The analysis demonstrated that the most significant pathways were associated with TLR receptor signaling and tolerance, I-kappa B kinase/NF-kappa B signaling, and MyD88-independent TLR signaling. This systematic review uncovered gene expression variations in several candidate genes and identified a number of underlying biological pathways associated with rUTIs. These findings could shift the treatment and prevention strategies for rUTIs.

Identifiants

pubmed: 37917182
doi: 10.1007/s00192-023-05671-6
pii: 10.1007/s00192-023-05671-6
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The International Urogynecological Association.

Références

Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–84.
pubmed: 25853778 pmcid: 4457377 doi: 10.1038/nrmicro3432
Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:1756287219832172.
pubmed: 31105774 pmcid: 6502976 doi: 10.1177/1756287219832172
Al-Badr A, Al-Shaikh G. Recurrent urinary tract infections management in women: a review. Sultan Qaboos Univ Med J. 2013;13(3):359–67.
pubmed: 23984019 pmcid: 3749018 doi: 10.12816/0003256
Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202(2):282–9.
pubmed: 31042112 doi: 10.1097/JU.0000000000000296
Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5s–13s.
pubmed: 12113866 doi: 10.1016/S0002-9343(02)01054-9
Hopkins WJ, Heisey DM, Lorentzen DF, Uehling DT. A comparative study of major histocompatibility complex and red blood cell antigen phenotypes as risk factors for recurrent urinary tract infections in women. J Infect Dis. 1998;177(5):1296–301.
pubmed: 9593015 doi: 10.1086/515283
Grönberg-Hernández J, Sundén F, Connolly J, Svanborg C, Wullt B. Genetic control of the variable innate immune response to asymptomatic bacteriuria. PLoS One. 2011;6(11):e28289.
pubmed: 22140570 doi: 10.1371/journal.pone.0028289
Ching C, Schwartz L, Spencer JD, Becknell B. Innate immunity and urinary tract infection. Pediatr Nephrol. 2020;35(7):1183–92.
pubmed: 31197473 doi: 10.1007/s00467-019-04269-9
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
pubmed: 19622551 pmcid: 2714657 doi: 10.1136/bmj.b2535
Kellermeyer L, Harnke B, Knight S. Covidence and Rayyan. J Med Libr Assoc. 2018;106(4):580–3. https://doi.org/10.5195/jmla.2018.513 .
doi: 10.5195/jmla.2018.513 pmcid: 6148615
Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14(1):45.
pubmed: 24690082 pmcid: 4021422 doi: 10.1186/1471-2288-14-45
Santos WMD, Secoli SR, Püschel VAA. The Joanna Briggs Institute approach for systematic reviews. Rev Lat Am Enfermagem. 2018;26:e3074.
pubmed: 30462787 pmcid: 6248737 doi: 10.1590/1518-8345.2885.3074
Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Suppl_2):W214–20.
pubmed: 20576703 pmcid: 2896186 doi: 10.1093/nar/gkq537
Isali I, Mahran A, Khalifa AO, et al. Gene expression in stress urinary incontinence: a systematic review. Int Urogynecol J. 2020;31(1):1–14.
pubmed: 31312847 doi: 10.1007/s00192-019-04025-5
Mousavian Z, Khodabandeh M, Sharifi-Zarchi A, Nadafian A, Mahmoudi A. StrongestPath: a Cytoscape application for protein-protein interaction analysis. BMC Bioinformatics. 2021;22(1):352.
pubmed: 34187355 pmcid: 8244221 doi: 10.1186/s12859-021-04230-4
Frendéus B, Godaly G, Hang L, Karpman D, Svanborg C. Interleukin-8 receptor deficiency confers susceptibility to acute pyelonephritis. J Infect Dis. 2001;183(Suppl 1):S56–60.
pubmed: 11171016 doi: 10.1086/318848
Frendéus B, Godaly G, Hang L, Karpman D, Lundstedt AC, Svanborg C. Interleukin 8 receptor deficiency confers susceptibility to acute experimental pyelonephritis and may have a human counterpart. J Exp Med. 2000;192(6):881–90.
pubmed: 10993918 pmcid: 2193279 doi: 10.1084/jem.192.6.881
Lundstedt AC, McCarthy S, Gustafsson MC, et al. A genetic basis of susceptibility to acute pyelonephritis. PLoS One. 2007;2(9):e825.
pubmed: 17786197 pmcid: 1950574 doi: 10.1371/journal.pone.0000825
Lundstedt AC, Leijonhufvud I, Ragnarsdottir B, Karpman D, Andersson B, Svanborg C. Inherited susceptibility to acute pyelonephritis: a family study of urinary tract infection. J Infect Dis. 2007;195(8):1227–34.
pubmed: 17357062 doi: 10.1086/512620
Smithson A, Sarrias MR, Barcelo J, et al. Expression of interleukin-8 receptors (CXCR1 and CXCR2) in premenopausal women with recurrent urinary tract infections. Clin Diagn Lab Immunol. 2005;12(12):1358–63.
pubmed: 16339057 pmcid: 1317081
Ragnarsdóttir B, Samuelsson M, Gustafsson MC, Leijonhufvud I, Karpman D, Svanborg C. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis. 2007;196(3):475–84.
pubmed: 17597463 doi: 10.1086/518893
Raghuwanshi SK, Su Y, Singh V, Haynes K, Richmond A, Richardson RM. The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. J Immunol. 2012;189(6):2824–32.
pubmed: 22869904 doi: 10.4049/jimmunol.1201114
Morris SW, Nelson N, Valentine MB, et al. Assignment of the genes encoding human interleukin-8 receptor types 1 and 2 and an interleukin-8 receptor pseudogene to chromosome 2q35. Genomics. 1992;14(3):685–91.
pubmed: 1427896 doi: 10.1016/S0888-7543(05)80169-7
Bertini R, Barcelos LS, Beccari AR, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. Br J Pharmacol. 2012;165(2):436–54.
pubmed: 21718305 pmcid: 3268197 doi: 10.1111/j.1476-5381.2011.01566.x
Godaly G, Hang L, Frendéus B, Svanborg C. Transepithelial neutrophil migration is CXCR1 dependent in vitro and is defective in IL-8 receptor knockout mice. J Immunol. 2000;165(9):5287–94.
pubmed: 11046063 doi: 10.4049/jimmunol.165.9.5287
Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev. 2003;16(4):637–46.
pubmed: 14557290 pmcid: 207104 doi: 10.1128/CMR.16.4.637-646.2003
Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1–14.
pubmed: 15585605 doi: 10.1093/intimm/dxh186
Nahid MA, Satoh M, Chan EK. MicroRNA in TLR signaling and endotoxin tolerance. Cell Mol Immunol. 2011;8(5):388–403.
pubmed: 21822296 pmcid: 3618661 doi: 10.1038/cmi.2011.26
Butcher SK, O'Carroll CE, Wells CA, Carmody RJ. Toll-like like receptors drive specific patterns of tolerance and training on restimulation of macrophages. Front Immunol. 2018;9:933.
pubmed: 29867935 pmcid: 5960718 doi: 10.3389/fimmu.2018.00933
Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2021;78(4):1233–61.
pubmed: 33057840 doi: 10.1007/s00018-020-03656-y
Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301(5633):640–3.
pubmed: 12855817 doi: 10.1126/science.1087262
Nilsen NJ, Vladimer GI, Stenvik J, et al. A role for the adaptor proteins TRAM and TRIF in toll-like receptor 2 signaling. J Biol Chem. 2015;290(6):3209–22.
pubmed: 25505250 doi: 10.1074/jbc.M114.593426
Riva F, Bonavita E, Barbati E, Muzio M, Mantovani A, Garlanda C. TIR8/SIGIRR is an interleukin-1 receptor/Toll like receptor family member with regulatory functions in inflammation and immunity. Front Immunol. 2012;3:322.
pubmed: 23112799 pmcid: 3482685 doi: 10.3389/fimmu.2012.00322
Li D, Zhang X, Chen B. SIGIRR participates in negative regulation of LPS response and tolerance in human bladder epithelial cells. BMC Immunol. 2015;16(1):73.
pubmed: 26634342 pmcid: 4669620 doi: 10.1186/s12865-015-0137-5
Yu W, Haque I, Venkatraman A, Menden HL, Mabry SM, Roy BC, et al. SIGIRR mutation in human necrotizing enterocolitis (NEC) disrupts STAT3-dependent microRNA expression in neonatal gut. Cell Mol Gastroenterol Hepatol. 2022;13(2):425–40.
pubmed: 34563711 doi: 10.1016/j.jcmgh.2021.09.009
Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic Escherichia coli (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. Front Microbiol. 2017;8:1566.
pubmed: 28861072 pmcid: 5559502 doi: 10.3389/fmicb.2017.01566
Bien J, Sokolova O, Bozko P. Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage. Int J Nephrol. 2012;2012:681473.
pubmed: 22506110 pmcid: 3312279 doi: 10.1155/2012/681473
Yadav M, Zhang J, Fischer H, et al. Inhibition of TIR domain signaling by TcpC: MyD88-dependent and independent effects on Escherichia coli virulence. PLoS Pathog. 2010;6(9):e1001120.
pubmed: 20886104 pmcid: 2944809 doi: 10.1371/journal.ppat.1001120
Dobrindt U, Wullt B, Svanborg C. Asymptomatic bacteriuria as a model to study the coevolution of hosts and bacteria. Pathogens. 2016;5(1):21.
pubmed: 26891332 pmcid: 4810142 doi: 10.3390/pathogens5010021
Spencer JD, Schwaderer AL, Becknell B, Watson J, Hains DS. The innate immune response during urinary tract infection and pyelonephritis. Pediatr Nephrol. 2014;29(7):1139–49.
pubmed: 23732397 doi: 10.1007/s00467-013-2513-9
Ambite I, Lutay N, Stork C, Dobrindt U, Wullt B, Svanborg C. Bacterial suppression of RNA polymerase II-dependent host gene expression. Pathogens. 2016;5(3):49
pubmed: 27420101 pmcid: 5039429 doi: 10.3390/pathogens5030049
Zanoni I, Granucci F. Role of CD14 in host protection against infections and in metabolism regulation. Front Cell Infect Microbiol. 2013;3:32.
pubmed: 23898465 pmcid: 3721004 doi: 10.3389/fcimb.2013.00032
Schreiber HL t, Conover MS, et al. Bacterial virulence phenotypes of Escherichia coli and host susceptibility determine risk for urinary tract infections. Sci Transl Med. 2017;9(382):eaaf1283.
pubmed: 28330863 pmcid: 5653229 doi: 10.1126/scitranslmed.aaf1283
Zaffanello M, Malerba G, Cataldi L, et al. Genetic risk for recurrent urinary tract infections in humans: a systematic review. J Biomed Biotechnol. 2010;2010:321082.
pubmed: 20379347 pmcid: 2847765 doi: 10.1155/2010/321082
Sorić Hosman I, Cvitković Roić A, Lamot L. A systematic review of the (un)known host immune response biomarkers for predicting recurrence of urinary tract infection. Front Med (Lausanne). 2022;9:931717.
pubmed: 35860746 doi: 10.3389/fmed.2022.931717
Zaffanello M, Tardivo S, Cataldi L, Fanos V, Biban P, Malerba G. Genetic susceptibility to renal scar formation after urinary tract infection: a systematic review and meta-analysis of candidate gene polymorphisms. Pediatr Nephrol. 2011;26(7):1017–29.
pubmed: 21116828 doi: 10.1007/s00467-010-1695-7

Auteurs

Ilaha Isali (I)

Department of Urology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.

Thomas R Wong (TR)

Department of Urology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.

Ali Furkan Batur (AF)

Department of Urology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.

Chen-Han Wilfred Wu (CW)

Department of Urology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Fredrick R Schumacher (FR)

Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.

Rachel Pope (R)

Department of Urology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.

Adonis Hijaz (A)

Department of Urology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.

David Sheyn (D)

Department of Urology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA. David.Sheyn@uhhospitals.org.

Classifications MeSH